Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Construction in Progress (2022 - 2025)

Apyx Medical filings provide 4 years of Construction in Progress readings, the most recent being $162000.0 for Q4 2025.

  • On a quarterly basis, Construction in Progress fell 74.49% to $162000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $162000.0, a 74.49% decrease, with the full-year FY2025 number at $162000.0, down 74.49% from a year prior.
  • Construction in Progress hit $162000.0 in Q4 2025 for Apyx Medical, down from $635000.0 in the prior quarter.
  • In the past five years, Construction in Progress ranged from a high of $635000.0 in Q4 2024 to a low of $162000.0 in Q4 2025.
  • Median Construction in Progress over the past 4 years was $507000.0 (2022), compared with a mean of $463571.4.
  • Biggest five-year swings in Construction in Progress: soared 58.75% in 2024 and later tumbled 74.49% in 2025.
  • Apyx Medical's Construction in Progress stood at $507000.0 in 2022, then dropped by 21.1% to $400000.0 in 2023, then soared by 58.75% to $635000.0 in 2024, then plummeted by 74.49% to $162000.0 in 2025.
  • The last three reported values for Construction in Progress were $162000.0 (Q4 2025), $635000.0 (Q4 2024), and $400000.0 (Q4 2023) per Business Quant data.